TCT-8 Updated 30-Day Outcomes for the U.S. Early Feasibility Study of the SAPIEN M3 Transcatheter Mitral Valve Replacement System

Raj Makkar,William W. O’Neill,Brian Whisenant,Mayra Guerrero,Ted Feldman,Chet Rihal,Jeremy Gorelick,John G. Webb

TCT-8 Updated 30-Day Outcomes for the U.S. Early Feasibility Study of the SAPIEN M3 Transcatheter Mitral Valve Replacement System

2019

Raj Makkar
William W. O’Neill
Brian Whisenant
Mayra Guerrero
Ted Feldman
Chet Rihal
Jeremy Gorelick
John G. Webb

Our aim was to determine the initial technical feasibility, clinical safety, and efficacy of the SAPIEN M3 System in patients with severe mitral regurgitation (MR). Mitral valve surgery is currently recommended in patients with severe, symptomatic MR. The SAPIEN M3 System is a novel, transvenous,

Keywords:

Mitral valve replacement
Cardiology
Internal medicine
Medicine
mitral regurgitation
mitral valve surgery
clinical safety
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations